GlassScriptPhysician profile
Edwin J Crosier
NPI 1447559752
$3,671.81
in general payments reported to CMS, 2019-2025
30 companies · $2,058 in 2025
The $2,058 reported for 2025 was more than what 96% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,614 · 2025: $2,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,671.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $556.99 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $483.43 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $362.97 | 2024-2025 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $177.88 | 2024-2025 | Isturisa, Signifor Lar |
| Xeris Pharmaceuticals, INC. | $169.55 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Sequel Med Tech, LLC | $162.25 | 2025 | Twiist |
| Novartis Pharmaceuticals Corporation | $159.47 | 2024-2025 | |
| Amgen INC. | $155.13 | 2024-2025 | Repatha, Repatha |
| Mannkind Corporation | $122.69 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.53 | 2024 | |
| Sanofi-Aventis U.S. LLC | $108.54 | 2025 | |
| Beta Bionics, INC. | $107.41 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Madrigal Pharmaceuticals | $104.28 | 2025 | Rezdiffra |
| Ibsa Pharma INC. | $98.10 | 2024-2025 | Tirosint, Licart, Flector |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.08 | 2024-2025 | Jardiance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $91.37 | 2024-2025 | Korlym |
| Globus Medical, INC. | $77.99 | 2025 | Senza |
| Amphastar Pharmaceuticals, INC. | $77.12 | 2024-2025 | |
| Radius Health, INC. | $63.26 | 2024-2025 | Tymlos |
| Medtronic, INC. | $60.92 | 2024-2025 | Inceptiv, Intellis Adaptivestim |
| Esperion Therapeutics, INC. | $56.98 | 2024-2025 | Nexletol |
| Ascendis Pharma Endocrinology INC | $50.06 | 2025 | Yorvipath |
| Nevro Corp. | $39.97 | 2024 | Senza |
| Abbott Laboratories | $37.04 | 2025 | Freestyle Libre 3 |
| Antares Pharma, INC. | $34.06 | 2024-2025 | Xyosted |
| Sandoz INC. | $30.57 | 2025 | Jubbonti |
| Acella Pharmaceuticals, LLC | $22.87 | 2025 | NP Thyroid 60 |
| Kyowa Kirin, INC. | $22.01 | 2025 | |
| Rhythm Pharmaceuticals, INC. | $19.34 | 2024 | Imcivree |
| Amneal Pharmaceuticals LLC | $13.95 | 2024 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Crosier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.